AAM Statement on Oil States Energy Services v. Greene's Energy Group

AAM commends the Supreme Court for upholding the constitutionality of the Inter Partes Review (IPR) process. This is a win for patients who depend on continued access to safe, effective and affordable generic and biosimilar medicines. IPR helps enhance patient access to generic and biosimilar medicines by providing a more efficient mechanism for determining whether the patents of brand-name drug manufacturers are valid.

ATTRIBUTE TO: Jeff Francer, Senior Vice President & General Counsel

View Amicus Brief


Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.